The United States Food and Drug Administration (FDA) has officially expanded the approved indication for Bristol Myers Squibb’s (BMS) flagship…
Read More
Affinia Therapeutics Secures FDA Orphan Drug Designation for AFTX-201, a Promising Gene Therapy for BAG3-Associated Dilated Cardiomyopathy
Affinia Therapeutics has announced a significant milestone in the development of its investigational gene therapy, AFTX-201, with the US Food…
Read More
US FDA Grants Priority Review to Bristol Myers Squibb’s Camzyos for Adolescent Patients with Obstructive Hypertrophic Cardiomyopathy
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental new drug application (sNDA) for Camzyos…
Read More
